A Phase 2 interventional study of Tapinarof cream, 1% in Plaque Psoriasis, sponsored by Organon and Co. Completed at 6 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-19.
Sponsored by Organon and Co · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing tapinarof in Psoriasis — 3 open to participants now, 3 under way, 1 of them phase 3. tapinarof · Psoriasis.
Among the 19 studies testing tapinarof in Psoriasis, this one is the 16th largest by enrollment, is one of 4 that started in 2019, is one of 3 in phase 2, and was the 9th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →3 of the 19 studies testing tapinarof in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:
Wake Forest University Health Sciences · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
Pakistan Institute of Medical Sciences · Sites in Pakistan
Ages 18–65
By country, each count listing its studies:
tapinarof: first FDA approval 2022 (VTAMA). What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 6 · Phase 4 6
First in 2010; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 21 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 58 across the 19 interventional studies. Of the 12 that completed or were terminated, 7 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
Organon & Co. has 8 studies filed under Psoriasis — fewer than ten, so there is no comparison to draw.
1 of the studies testing tapinarof in Psoriasis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05981118Phase 3Wake Forest University Health SciencesComparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant) | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing tapinarof in Psoriasis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, multicenter study to evaluate the systemic exposure and safety of topical tapinarof cream, 1% under conditions of maximal use in adults with plaque psoriasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tapinarof (DMVT-505) cream, 1% applied topically once daily
Drug: Tapinarof cream, 1%
Tapinarof cream, 1% applied topically once daily
Also known as: DMVT-505
Number of Participants That Experienced Adverse Events (AEs), Severe Adverse Events, and Serious Adverse Events (SAEs)
Frequency and severity of AEs (local and systemic)
Time frame: Baseline to Week 4
Number of Participants With Clinically Significant Changes From Baseline in Laboratory Values, Biomarker Values, ECG Results or Vital Signs
Changes in laboratory values, biomarker values, ECG results and vital signs were assessed for clinical relevance.
Time frame: Baseline to Week 4 or Follow-Up (7-10 days after Week 4 Visit)
Number of Participants With Irritation as Assessed by the Local Tolerability Scale
At each specified study visit, the Investigator (or qualified evaluator) assessed the presence and overall degree of irritation at the application sites, according to the LTS. The score will ideally represent an 'average' across all application sites. To the fullest extent possible, the same Investigator (or designated evaluator) will perform all tolerability assessments for an individual participant throughout the study.
Time frame: Day 1, Day 15, Day 29
Tapinarof and Tapinarof Sulfate (Metabolite) Plasma PK Parameters on Day 1 and Day 29: AUCo-tau
The AUC in plasma is a pharmacokinetic parameter that describes the overall exposure of the drug.
Time frame: Day 1 and Day 29 (PK samples collected at pre-dose and at 1, 2, 3, 4, 5, 8, 12, and 24 hours after dosing)
Tapinarof and Tapinarof Sulfate (Metabolite) Plasma PK Parameters on Day 1 and Day 29: Cmax
The Cmax is a pharmacokinetic parameter that describes the highest concentration of the drug that is achieved after dosing.
Time frame: Day 1 and Day 29 (PK samples collected at pre-dose and at 1, 2, 3, 4, 5, 8, 12, and 24 hours after dosing)
Tapinarof and Tapinarof Sulfate (Metabolite) Plasma PK Parameters on Day 1 and Day 29: Tmax and t1/2
The tmax is a pharmacokinetic parameter that describes the time point at which the highest concentration of the drug is achieved after dosing.
Time frame: Day 1 and Day 29 (PK samples collected at pre-dose and at 1, 2, 3, 4, 5, 8, 12, and 24 hours after dosing)
Change From Baseline in QTcF (ΔQTcF) at Each Post-treatment Time Point on the Sampling Day With the Higher Cmax (Day 1 or Day 29)
Identify clinically relevant effect of tapinarof on cardiac conduction
Time frame: Baseline and Day 1
Analysis of the Relationship Between Plasma Concentration and ΔQTcF
The relationship between tapinarof plasma concentrations and ∆QTcF was investigated using a linear mixed-effects modeling approach with ΔQTcF as the dependent variable. A linear model with an intercept was fitted for tapinarof plasma concentrations, which represented the data in an acceptable way. The slope of tapinarof plasma concentration in the concentration-QTc relationship was estimated.
Time frame: Day 1
Mean Change From Baseline to Day 29 in Physician's Global Assessment (PGA)
The PGA is a clinical tool for assessing the current state/severity of a subject's psoriasis at a given timepoint. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, scaling, and plaque thickness/elevation as guidelines. Higher PGA scores represent more severe disease. This scale ranges from 0 to 5, with 0 = best outcome.
Time frame: Baseline to Day 29
Mean Change From Baseline to Day 29 Psoriasis Area and Severity Index (PASI)
The Psoriasis Area and Severity Index (PASI) scoring system combines the assessment of lesion severity and extent of affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, and legs). Each area is assessed for 3 signs: erythema (redness), induration (plaque thickness), and scale. The severity of each sign in each body area is assessed and scored independently using a 5-point scale, where 0=none, 1=slight, 2=mild, 3=moderate, 4=severe. Each area is also assessed for percent of skin involved: 0 = (0%), 1 = (1-\<10%), 2 = (10-\<30%), 3 = (30-\<50%), 4 = (50 -\<70%), 5 = (70-\<90%), 6 = (90-100%). The individual scores are multiplied by a weighted factor for each body region; the sum of these scores gives the overall PASI score. Higher scores indicate more severe disease. PASI is a static assessment made without reference to previous scores.
Time frame: Baseline to Day 29
Mean Change From Baseline to Day 29 in Percent of Total Body Surface Area (%BSA) Affected
The assessment of %BSA affected is an estimate of the percentage of total involved skin with psoriasis. For the purpose of clinical estimation, the total palmar surface of the subject's palm and digits may be assumed to be approximately equivalent to 1% BSA. The %BSA affected by psoriasis will be evaluated (from 0% to 100%). %BSA is a static assessment made without reference to previous scores.
Time frame: Baseline to Day 29
| Milestone | Tapinarof (DMVT-505) Cream, 1% |
|---|---|
| Started | 21 |
| Completed | 19 |
| Not completed | 2 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Withdrawal by subject | 1 |
Frequency and severity of AEs (local and systemic)
| Participants | Tapinarof (DMVT-505) Cream, 1% |
|---|---|
| Experienced an AE | 12 |
| Experienced a Treatment-Related AE | 6 |
| Experienced a Grade 3 (severe) AE | 2 |
| Experienced a Grade 4 (life-threatening) AE | 0 |
| Experienced a Grade 5 (fatal) AE | 0 |
| Experienced an SAE | 1 |
| Experienced a Treatment-related SAE | 0 |
| Experienced TEAE leading to discontinuation from study/drug | 0 |
Changes in laboratory values, biomarker values, ECG results and vital signs were assessed for clinical relevance.
| Participants | Tapinarof (DMVT-505) Cream, 1% |
|---|---|
| Clinically Meaningful changes in hematology. | 0 |
| Clinically meaningful changes in chemistry | 0 |
| Clinically meaningful changes in urinalysis | 0 |
| Clinically meaningful changes in tryptase | 0 |
| Clinically meaningful changes in ECG parameters | 0 |
| Clinically meaningful changes in vital signs | 0 |
At each specified study visit, the Investigator (or qualified evaluator) assessed the presence and overall degree of irritation at the application sites, according to the LTS. The score will ideally represent an 'average' across all application sites. To the fullest extent possible, the same Investigator (or designated evaluator) will perform all tolerability assessments for an individual participant throughout the study.
| Participants | Tapinarof (DMVT-505) Cream, 1% |
|---|---|
| Baseline — No Irritation | 14 |
| Baseline — Mild | 5 |
| Baseline — Moderate | 1 |
| Baseline — Severe | 1 |
| Baseline — Very Severe | 0 |
| Day 15 — No Irritation | 14 |
| Day 15 — Mild | 5 |
| Day 15 — Moderate | 1 |
| Day 15 — Severe | 0 |
| Day 15 — Very Severe | 0 |
| Day 29 — No Irritation | 17 |
| Day 29 — Mild | 2 |
| Day 29 — Moderate | 0 |
| Day 29 — Severe | 0 |
| Day 29 — Very Severe | 0 |
The AUC in plasma is a pharmacokinetic parameter that describes the overall exposure of the drug.
| pg*h/ml | Tapinarof (DMVT-505) Cream, 1% |
|---|---|
| Day 1: tapinarof | 8037.29 ± 6204.935 |
| Day 29: tapinarof | 1985.54 ± NA |
The Cmax is a pharmacokinetic parameter that describes the highest concentration of the drug that is achieved after dosing.
| pg/mL | Tapinarof (DMVT-505) Cream, 1% |
|---|---|
| Day 1: tapinarof Cmax | 898.33 ± 1448.084 |
| Day 29: tapinarof Cmax | 116.09 ± 148.424 |
The tmax is a pharmacokinetic parameter that describes the time point at which the highest concentration of the drug is achieved after dosing.
| hours | Tapinarof (DMVT-505) Cream, 1% |
|---|---|
| Day 1: tmax | 4.39 ± 5.476 |
| Day 29: tmax | 4.02 ± 3.005 |
| Day 1: t1/2 | 6.41 ± 0.691 |
Identify clinically relevant effect of tapinarof on cardiac conduction
| ms | Tapinarof (DMVT-505) Cream, 1% |
|---|---|
| Day 1 1 h Post-dose | -7.2 ± 1.79 |
| Day 1 2 h Post-dose | -1.1 ± 2.92 |
| Day 1 3 h Post-dose | -4.3 ± 1.88 |
| Day 1 4 h Post-dose | -2.3 ± 3.04 |
| Day 1 5 h Post-dose | -4.9 ± 2.87 |
| Day 1 8 h Post-dose | -3.0 ± 2.60 |
| Day 1 12 h Post-dose | -1.6 ± 2.18 |
| Day 1 24 h Post-dose | -3.4 ± 1.97 |
The relationship between tapinarof plasma concentrations and ∆QTcF was investigated using a linear mixed-effects modeling approach with ΔQTcF as the dependent variable. A linear model with an intercept was fitted for tapinarof plasma concentrations, which represented the data in an acceptable way. The slope of tapinarof plasma concentration in the concentration-QTc relationship was estimated.
| ms per pg/ml | Tapinarof (DMVT-505) Cream, 1% |
|---|---|
| Analysis of the Relationship Between Plasma Concentration and ΔQTcF | -0.00016 (-0.002172 to 0.001844) |
The PGA is a clinical tool for assessing the current state/severity of a subject's psoriasis at a given timepoint. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, scaling, and plaque thickness/elevation as guidelines. Higher PGA scores represent more severe disease. This scale ranges from 0 to 5, with 0 = best outcome.
| score on a scale | Tapinarof (DMVT-505) Cream, 1% |
|---|---|
| Mean Change From Baseline to Day 29 in Physician's Global Assessment (PGA) | -1.2 ± 1.03 |
The Psoriasis Area and Severity Index (PASI) scoring system combines the assessment of lesion severity and extent of affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, and legs). Each area is assessed for 3 signs: erythema (redness), induration (plaque thickness), and scale. The severity of each sign in each body area is assessed and scored independently using a 5-point scale, where 0=none, 1=slight, 2=mild, 3=moderate, 4=severe. Each area is also assessed for percent of skin involved: 0 = (0%), 1 = (1-\<10%), 2 = (10-\<30%), 3 = (30-\<50%), 4 = (50 -\<70%), 5 = (70-\<90%), 6 = (90-100%). The individual scores are multiplied by a weighted factor for each body region; the sum of these scores gives the overall PASI score. Higher scores indicate more severe disease. PASI is a static assessment made without reference to previous scores.
| score on a scale | Tapinarof (DMVT-505) Cream, 1% |
|---|---|
| Mean Change From Baseline to Day 29 Psoriasis Area and Severity Index (PASI) | -15.14 (-19.61 to -10.66) |
The assessment of %BSA affected is an estimate of the percentage of total involved skin with psoriasis. For the purpose of clinical estimation, the total palmar surface of the subject's palm and digits may be assumed to be approximately equivalent to 1% BSA. The %BSA affected by psoriasis will be evaluated (from 0% to 100%). %BSA is a static assessment made without reference to previous scores.
| percentage of BSA affected | Tapinarof (DMVT-505) Cream, 1% |
|---|---|
| Mean Change From Baseline to Day 29 in Percent of Total Body Surface Area (%BSA) Affected | -14.44 (-19.84 to -9.04) |
Collected over Study Period (29 days) + Follow-up period (7 to 10 days). Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tapinarof (DMVT-505) Cream, 1% | 0/21 (0%) | 1/21 (4.8%) | 12/21 (57.1%) |
| Event | Tapinarof (DMVT-505) Cream, 1% |
|---|---|
| pancreatitisGastrointestinal disorders | 1/21 |
| Event | Tapinarof (DMVT-505) Cream, 1% |
|---|---|
| FolliculitisInfections and infestations | 4/21 |
| HeadacheNervous system disorders | 4/21 |
| Back painMusculoskeletal and connective tissue disorders | 2/21 |
| PruritusSkin and subcutaneous tissue disorders | 2/21 |
| Abdominal PainGastrointestinal disorders | 1/21 |
| NauseaGastrointestinal disorders | 1/21 |
| PancreatitisGastrointestinal disorders | 1/21 |
| Chest PainGeneral disorders | 1/21 |
| FatigueGeneral disorders | 1/21 |
| PainGeneral disorders | 1/21 |
| Age, Continuous(years) | Tapinarof (DMVT-505) Cream, 1% |
|---|---|
| Mean | 51.8 ± 13.91 |
| Sex: Female, Male(Participants) | Tapinarof (DMVT-505) Cream, 1% |
|---|---|
| Female | 8 |
| Male | 13 |
| Race (NIH/OMB)(Participants) | Tapinarof (DMVT-505) Cream, 1% |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 16 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2019 to primary completion in Jan 2020, 5 months.
Results were first posted in May 2022, 2 years 3 months after primary completion.
Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 5 months is below that.
Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tapinarof